癌症中的内素:表达模式,机械洞察力和治疗方法
Shiqi Lu1, Lunbiao Gan1, Tong Lu2
1Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi 710072, China.
Theranostics
|January 2, 2024
概括
内素 (TEM1/CD248),一种促进瘤生长和扩散的蛋白质,是癌症治疗的有希望的标. 研究审查了其作用和治疗策略,以改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 内素 (TEM1/CD248) 是一种涉及瘤进展的跨膜糖蛋白.
- 它表达在瘤肌体 (纤维细胞,细胞周细胞) 和肉瘤细胞中.
- 内素有助于瘤细胞的增殖,迁移,血管生成和免疫抑制.
研究的目的:
- 为了审查各种癌症类型的内素表达模式.
- 阐明内素促进瘤进展的机制.
- 总结目前针对内素的治疗策略.
主要方法:
- 关于不同癌症中的内素表达的文献综述.
- 对由内素驱动的瘤促进的记录机制的分析.
- 汇编了关于内素向治疗的数据.
主要成果:
- 内素在固体瘤和肉瘤中表现多样.
- 关键机制包括增强的增殖,粘附,迁移,血管生成和免疫抑制.
- 几种针对内素的抗体显示了初步的抗瘤活性.
结论:
- 内素是瘤进展的重要驱动因素,也是一个可行的治疗点.
- 向内沙林为新型癌症治疗提供了一个有前途的战略.
- 需要进一步开发基于内索的疗法.
关键词:
CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248 CD248在TEM1中,TEM1是TEM1.血管新生是因为血管新生.终极的终极的终极的终极有针对性的治疗.瘤微环境是一个微环境.瘤进展的进展情况更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Non-Canonical Wnt Signaling Pathways
7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Canonical Wnt Signaling Pathway
8.8K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


